

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

OLD ID & CONSTRUCT OF HACHTERDOLD CHASSO & CON	pass a rate onto consumono.
Application Number	10/644,308
Filing Date	AUGUST 19, 2003
First Named Inventor	JILL GILES-KOMAR
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 309 USA NP

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	U.S. Patent Do	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	
	NO.	NO.		(	·	пин-ос-уууу	
		<u> </u>					
	<del>                                     </del>						
	_		*		:		
	<del> </del>						
	ļ	<u> </u>					
		<u>}</u>					
				<del></del>		. 10	
	_					)	
	┞	-					
	L _						
	Γ.		e.ke				
	<u> </u>				<u> </u>		

Examiner Initials	Cite	Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
		Office <sup>3</sup>	Number <sup>4</sup> KindCode <sup>8</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Τ°
						40	
					×.	2.	
	,						

Signature Considered Considered Considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resp

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

COLO TO A CONSCIDOT OF INFORMATION WIRESS IT US	plays a valle Own Control Humber.
Application Number	10/644,308
Filing Date	AUGUST 19, 2003
First Named Inventor	Jill Giles-Komar
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 309 USA NP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T³
2		LONBERG ET AL, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Letter to Nature, 1994, 856-859, Vol. 368.	
$\overline{\omega}$		GREEN, LARRY, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," Journal of Immunological Methods, 1999, 11-23, Vol. 231.	
w/		LYMAN ET AL, "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor. A Proliferative Factor for Primitive Hematopoietic Cells," Cell, 1993, 1157-1167, Vol. 75.	
<i>σ</i> \		MARASKOVSKY ET AL, "Dramatic Increase in the Numbers of Functionally Mature Dendritic Cells in Fit3 Ligand-treated Mich: Multiple Dendritic Cell Subpopulations Identified," J. Exp. Med., 1996, 1953-1962, Vol. 184, The Rockefeller University Press.	
6		LE BON ET AL, "Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo," Immunity, 2001, 461-470, Vol. 14, Cell Press.	
<i>"</i>		COHEN ET AL, "Modulating the immune response to genetic immunization," J. Faseb, 1998, 1611-1626, Vol. 12.	
0		ROBINSON, HARRIET, "DNA Vaccines: Basic mechanism and immune responses (Review)," International Journal of Molecular Medicine, 1999, 549-555, Vol. 4.	
~		DONNELLY ET AL, "DNA Vaccines," Dev. Biol. Stand., 1998, 43-53, Vol. 95.	
	· · ·		
	<b>-</b>		
			_
	<del></del>		
<u></u>			
· · · · · · · · · · · · · · · · · ·	<b>-</b>		
	<del></del>		
	<del>                                     </del>		
	<del> </del>		
			-
	<del> </del>		_
	<del>                                     </del>		_
	<del> </del>		-
	<del> </del>	And the second s	$\vdash$
	i		L

Examiner Signature	<i>~</i>	Date Considered	9-30-05	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313-1450jn.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop: IDS – Patent Applications, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.